Complement disorders and hemolytic uremic syndrome

Catherine Joseph, Jyothsna Gattineni

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Complement mediated hemolytic uremic syndrome (aHUS) accounts for a significant proportion of non-shiga toxin HUS. The purpose of this review is to outline the pathophysiology, clinical features and therapeutic options for aHUS. RECENT FINDINGS: In the last decade, strides have been made in identifying several new disease-causing mutations in complement-regulating proteins. SUMMARY: Complement mediated HUS (aHUS) has a worse prognosis compared with shiga toxin mediated HUS, often resulting in end stage renal disease. Early identification of aHUS is crucial so that plasma therapy can be initiated. After renal transplantation, there is very high risk of disease recurrence and graft loss. Eculizumab and combined liver-kidney transplantation offer promise for improved prognosis.

Original languageEnglish (US)
Pages (from-to)209-215
Number of pages7
JournalCurrent Opinion in Pediatrics
Volume25
Issue number2
DOIs
StatePublished - Apr 2013

Fingerprint

Hemolytic-Uremic Syndrome
Kidney Transplantation
Shiga Toxin
Liver Transplantation
Chronic Kidney Failure
Complement System Proteins
Transplants
Recurrence
Mutation
Therapeutics
eculizumab

Keywords

  • Factor H
  • Factor I
  • Membrane cofactor protein
  • Plasma exchange

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Complement disorders and hemolytic uremic syndrome. / Joseph, Catherine; Gattineni, Jyothsna.

In: Current Opinion in Pediatrics, Vol. 25, No. 2, 04.2013, p. 209-215.

Research output: Contribution to journalArticle

@article{08de7fdd571a4521bd47d158e558be24,
title = "Complement disorders and hemolytic uremic syndrome",
abstract = "PURPOSE OF REVIEW: Complement mediated hemolytic uremic syndrome (aHUS) accounts for a significant proportion of non-shiga toxin HUS. The purpose of this review is to outline the pathophysiology, clinical features and therapeutic options for aHUS. RECENT FINDINGS: In the last decade, strides have been made in identifying several new disease-causing mutations in complement-regulating proteins. SUMMARY: Complement mediated HUS (aHUS) has a worse prognosis compared with shiga toxin mediated HUS, often resulting in end stage renal disease. Early identification of aHUS is crucial so that plasma therapy can be initiated. After renal transplantation, there is very high risk of disease recurrence and graft loss. Eculizumab and combined liver-kidney transplantation offer promise for improved prognosis.",
keywords = "Factor H, Factor I, Membrane cofactor protein, Plasma exchange",
author = "Catherine Joseph and Jyothsna Gattineni",
year = "2013",
month = "4",
doi = "10.1097/MOP.0b013e32835df48a",
language = "English (US)",
volume = "25",
pages = "209--215",
journal = "Current Opinion in Pediatrics",
issn = "1040-8703",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Complement disorders and hemolytic uremic syndrome

AU - Joseph, Catherine

AU - Gattineni, Jyothsna

PY - 2013/4

Y1 - 2013/4

N2 - PURPOSE OF REVIEW: Complement mediated hemolytic uremic syndrome (aHUS) accounts for a significant proportion of non-shiga toxin HUS. The purpose of this review is to outline the pathophysiology, clinical features and therapeutic options for aHUS. RECENT FINDINGS: In the last decade, strides have been made in identifying several new disease-causing mutations in complement-regulating proteins. SUMMARY: Complement mediated HUS (aHUS) has a worse prognosis compared with shiga toxin mediated HUS, often resulting in end stage renal disease. Early identification of aHUS is crucial so that plasma therapy can be initiated. After renal transplantation, there is very high risk of disease recurrence and graft loss. Eculizumab and combined liver-kidney transplantation offer promise for improved prognosis.

AB - PURPOSE OF REVIEW: Complement mediated hemolytic uremic syndrome (aHUS) accounts for a significant proportion of non-shiga toxin HUS. The purpose of this review is to outline the pathophysiology, clinical features and therapeutic options for aHUS. RECENT FINDINGS: In the last decade, strides have been made in identifying several new disease-causing mutations in complement-regulating proteins. SUMMARY: Complement mediated HUS (aHUS) has a worse prognosis compared with shiga toxin mediated HUS, often resulting in end stage renal disease. Early identification of aHUS is crucial so that plasma therapy can be initiated. After renal transplantation, there is very high risk of disease recurrence and graft loss. Eculizumab and combined liver-kidney transplantation offer promise for improved prognosis.

KW - Factor H

KW - Factor I

KW - Membrane cofactor protein

KW - Plasma exchange

UR - http://www.scopus.com/inward/record.url?scp=84875382274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875382274&partnerID=8YFLogxK

U2 - 10.1097/MOP.0b013e32835df48a

DO - 10.1097/MOP.0b013e32835df48a

M3 - Article

VL - 25

SP - 209

EP - 215

JO - Current Opinion in Pediatrics

JF - Current Opinion in Pediatrics

SN - 1040-8703

IS - 2

ER -